These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 11756146

  • 21. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
    Green NS, Barral S.
    Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
    [Abstract] [Full Text] [Related]

  • 22. Adherence to hydroxyurea therapy in children with sickle cell anemia.
    Thornburg CD, Calatroni A, Telen M, Kemper AR.
    J Pediatr; 2010 Mar; 156(3):415-9. PubMed ID: 19880135
    [Abstract] [Full Text] [Related]

  • 23. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK, McCarthy WF, Guo N, Brugnara C, Kling G, Bauserman RL, Waclawiw MA.
    Hemoglobin; 2010 Mar; 34(5):424-9. PubMed ID: 20854115
    [Abstract] [Full Text] [Related]

  • 24. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.
    Walker AL, Steward S, Howard TA, Mortier N, Smeltzer M, Wang YD, Ware RE.
    Blood; 2011 Nov 17; 118(20):5664-70. PubMed ID: 21921042
    [Abstract] [Full Text] [Related]

  • 25. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.
    JAMA; 2003 Apr 02; 289(13):1645-51. PubMed ID: 12672732
    [Abstract] [Full Text] [Related]

  • 26. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP.
    Semin Oncol; 1992 Jun 02; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [Abstract] [Full Text] [Related]

  • 27. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
    Green NS, Manwani D, Qureshi M, Ireland K, Sinha A, Smaldone AM.
    Pediatr Blood Cancer; 2016 Dec 02; 63(12):2146-2153. PubMed ID: 27573582
    [Abstract] [Full Text] [Related]

  • 28. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea.
    Nottage KA, Ware RE, Winter B, Smeltzer M, Wang WC, Hankins JS, Dertinger SD, Shulkin B, Aygun B.
    Eur J Haematol; 2014 Nov 02; 93(5):377-83. PubMed ID: 24796940
    [Abstract] [Full Text] [Related]

  • 29. Long-term use of hydroxyurea for sickle cell anemia.
    Hagar W.
    JAMA; 2003 Aug 13; 290(6):753; author reply 754. PubMed ID: 12915424
    [No Abstract] [Full Text] [Related]

  • 30. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
    Nnebe-Agumadu U, Adebayo I, Erigbuem I, James E, Kumode E, Nnodu O, Adekile A.
    Pediatr Blood Cancer; 2021 Jun 13; 68(6):e28969. PubMed ID: 33788390
    [Abstract] [Full Text] [Related]

  • 31. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 13; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

  • 32. Determinants of fetal hemoglobin response to hydroxyurea.
    Steinberg MH.
    Semin Hematol; 1997 Jul 13; 34(3 Suppl 3):8-14. PubMed ID: 9317196
    [Abstract] [Full Text] [Related]

  • 33. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
    Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G, Platt OS.
    Blood; 1992 May 15; 79(10):2555-65. PubMed ID: 1375104
    [Abstract] [Full Text] [Related]

  • 34. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K, Smith-Whitley K.
    Semin Hematol; 1997 Jul 15; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [Abstract] [Full Text] [Related]

  • 35. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
    Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J.
    Blood; 2000 Oct 01; 96(7):2379-84. PubMed ID: 11001887
    [Abstract] [Full Text] [Related]

  • 36. Hydroxycarbamide: clinical aspects.
    Ware RE.
    C R Biol; 2013 Mar 01; 336(3):177-82. PubMed ID: 23643402
    [Abstract] [Full Text] [Related]

  • 37. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
    Tolu SS, Crouch A, Choi J, Gao Q, Reyes-Gil M, Ogu UO, Vinces G, Minniti CP.
    Ann Hematol; 2022 Mar 01; 101(3):541-548. PubMed ID: 35039901
    [Abstract] [Full Text] [Related]

  • 38. Hydroxyurea in children: present and future.
    Vichinsky EP.
    Semin Hematol; 1997 Jul 01; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [Abstract] [Full Text] [Related]

  • 39. Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia.
    Yahouédéhou SCMA, da Guarda CC, Figueiredo CVB, Santiago RP, Carvalho SP, Fiuza LM, Ndidi US, Oliveira RM, Carvalho MOS, Nascimento VML, Rocha LC, Lyra IM, Adorno EV, Goncalves MS.
    PLoS One; 2019 Jul 01; 14(7):e0218040. PubMed ID: 31306416
    [Abstract] [Full Text] [Related]

  • 40. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.
    Flanagan JM, Steward S, Howard TA, Mortier NA, Kimble AC, Aygun B, Hankins JS, Neale GA, Ware RE.
    Br J Haematol; 2012 Apr 01; 157(2):240-8. PubMed ID: 22360576
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.